REM) for total cholesterol, 3.70 [7.39, 0.00] mg/dl (P = 0.05
Outcomes vary depending on dose, presence or absence of type 2 diabetes, starting weight, and lifestyle factors such as diet and exercise
Improved Metabolic Health: In addition to supporting weight loss, Tirzepatide has been shown to improve blood sugar control, lower cholesterol, and reduce the risk of heart disease and other related conditions
The oral non-peptide GLP-1 receptor agonist market was dominated by North America in 2025 due to the high prevalence of obesity and diabetes, strong pharmaceutical research capabilities, and widespread adoption of innovative therapeutics
Semaglutide suppresses appetite, leading to reduced calorie intake